Pfizer Inc. is vulnerable to the possibility that President Donald Trump will place tariffs on the European Union, where the ...

Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's drug pipeline, vaccines and more.

Pfizer shares rose early Tuesday due to higher than expected demand for its COVID vaccine, but quickly sunk 2.3% after ...

Pfizer was quick to point out Read’s achievements in his role as CEO, which he took up in 2010 – 30 FDA approvals, and a 70% increase in annual dividends to $1.36.

Pfizer’s chief executive said he was “disappointed” with Robert F Kennedy Jr’s refusal to disavow the debunked link between vaccines and autism, even as he expressed confidence that the Trump ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health ...

The $150 billion company CEO revealed the ... with the release of Pfizer’s annual earnings report, which reflected revenues of $63.6 billion. In the announcement, Bourla stated: “I’m excited ...

Pfizer's CEO said that he had dinner with President Donald Trump's pick for health secretary, Robert F. Kennedy Jr. In a Tuesday earnings call, CEO Albert Bourla said Trump had introduced him to ...

In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.